Clinical Trial Update: Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion [Phase 1]

View source ↗

Summary

Phase 1 trial update examining whether Lucentis (ranibizumab) influences psychological morbidity, including depression, in patients with retinal vein occlusion …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Branch Retinal Vein Occlusion
• Central Retinal Vein Occlusion
• Major Depressive Disorder
• Retinal Vein Occlusion

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Retina Associates of Cleveland, Inc | Conditions: Venous Retinal Branch Occlusion, Central Retinal Vein Occlusion | Phase 1 | Status: UNKNOWN